Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karin Halevi–Tobias"'
Autor:
Avi Gillis, Michael Beil, Karin Halevi-Tobias, Peter Vernon van Heerden, Sigal Sviri, Zvia Agur
Publikováno v:
Intensive Care Medicine Experimental, Vol 7, Iss 1, Pp 1-16 (2019)
Abstract Background Sepsis-associated immune dysregulation, involving hyper-inflammation and immunosuppression, is common in intensive care patients, often leading to multiple organ dysfunction and death. The aim of this study was to identify the mai
Externí odkaz:
https://doaj.org/article/df32d085bed4470e9c7b2d80ec5ddb9a
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0179888 (2017)
Despite considerable investigational efforts, no method to overcome the pathogenesis caused by loss of function (LoF) mutations in tumor suppressor genes has been successfully translated to the clinic. The most frequent LoF mutation in human cancers
Externí odkaz:
https://doaj.org/article/cafa3ac485bd4a708bf99537253e8b6f
Autor:
Natalie Kronik, Yuri Kogan, Moran Elishmereni, Karin Halevi-Tobias, Stanimir Vuk-Pavlović, Zvia Agur
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e15482 (2010)
Therapeutic vaccination against disseminated prostate cancer (PCa) is partially effective in some PCa patients. We hypothesized that the efficacy of treatment will be enhanced by individualized vaccination regimens tailored by simple mathematical mod
Externí odkaz:
https://doaj.org/article/952b59b0344e4d87863189ace83d4920
PDF file - 201K, The contents of the document: 1. Model equations for the vaccine and the maturing DCs 2. Formal description of the algorithm for in-treatment therapy personalization 3. Success-of-validation criteria 4. Model comparison grade and par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::601a233934357fc933ae2a19eb2fb6c5
https://doi.org/10.1158/0008-5472.22396031
https://doi.org/10.1158/0008-5472.22396031
Publikováno v:
Expert Opinion on Biological Therapy. 16:1373-1385
Recently, cancer immunotherapy has shown considerable success, but due to the complexity of the immune-cancer interactions, clinical outcomes vary largely between patients. A possible approach to overcome this difficulty may be to develop new methodo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a982eecd508e54c08c4225efff14a1
https://doi.org/10.1080/14712598.2016.1223622
https://doi.org/10.1080/14712598.2016.1223622
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0179888 (2017)
PLoS ONE
PLoS ONE
Background Despite considerable investigational efforts, no method to overcome the pathogenesis caused by loss of function (LoF) mutations in tumor suppressor genes has been successfully translated to the clinic. The most frequent LoF mutation in hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468379ebe9e12f8694c246d95ae93cd6
http://europepmc.org/articles/PMC5510801?pdf=render
http://europepmc.org/articles/PMC5510801?pdf=render
Publikováno v:
Cancer Research. 72:2218-2227
Although therapeutic vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare. An improved understanding of patient-specific dynamic interactions of immunity and tumor progression, combined with personalized app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d04bfaff5b80dc168dcc6fae8aee36a8
https://doi.org/10.1158/0008-5472.can-11-4166
https://doi.org/10.1158/0008-5472.can-11-4166
Publikováno v:
Vrije Universiteit Brussel
The Wnt signalling pathway controls cell proliferation and differentiation, and its deregulation is implicated in different diseases including cancer. Learning how to manipulate this pathway could substantially contribute to the development of therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad0f2f1dd7629ad94b451cf930ace9c
https://hdl.handle.net/20.500.14017/35a4427e-bbdd-441d-b9d4-4fb3afecf2b2
https://hdl.handle.net/20.500.14017/35a4427e-bbdd-441d-b9d4-4fb3afecf2b2
Autor:
Karin Halevi-Tobias, Yuri Kogan, Natalie Kronik, Zvia Agur, Stanimir Vuk-Pavlović, Moran Elishmereni
Publikováno v:
PLoS ONE, Vol 5, Iss 12, p e15482 (2010)
PLoS ONE
PLoS ONE
Background: Therapeutic vaccination against disseminated prostate cancer (PCa) is partially effective in some PCa patients. We hypothesized that the efficacy of treatment will be enhanced by individualized vaccination regimens tailored by simple math
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f15afc67d1c449e79750101a49dba2f6
http://europepmc.org/articles/PMC2999571?pdf=render
http://europepmc.org/articles/PMC2999571?pdf=render